Form 4 for GUTS FRACTYL HEALTH, INC.
Accepted 2025-02-03 00:00:00 ET · period of report 2025-01-30 · accession 0000950170-25-012530 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-02-03 | 2025-01-30+ | GUTS | Caplan Jay David | Pres, Chief Product Off | M - OptEx | $1.70 | +43.8K | 175.9K | +33% | +$74.5K |
| DMT | 2025-02-03 | 2025-01-30+ | GUTS | Caplan Jay David | Pres, Chief Product Off | S - Sale+OE | $1.88 | -43.8K | 153.5K | -22% | -$82.3K |
| DMT | 2025-02-03 | 2025-01-30+ | GUTS | Caplan Jay David | Pres, Chief Product Off | M - OptEx | $0.00 | -43.8K | 40.3K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-30 | M | A | 21,472 | $1.70 | 175,016 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-30 | S | D | 21,472 | $1.95 | 153,544 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.9000 to $2.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-01-31 | M | A | 22,346 | $1.70 | 175,890 | D | — | — | |
| 4 | Common | Common Stock | 2025-01-31 | S | D | 22,346 | $1.81 | 153,544 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8000 to $1.8800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option | 2025-01-31 | M | D | 22,346 | $0.00 | 17,924 | D | $1.70 · — to 2025-02-10 | 22,346 Common Stock | (F4) The option is fully vested and exercisable. |
| 6 | Derivative | Stock Option | 2025-01-30 | M | D | 21,472 | $0.00 | 40,270 | D | $1.70 · — to 2025-02-10 | 21,472 Common Stock | (F4) The option is fully vested and exercisable. |